LAVA Therapeutics (LVTX) Competitors $1.43 -0.03 (-2.05%) Closing price 07/25/2025 03:50 PM EasternExtended Trading$1.46 +0.03 (+1.75%) As of 07/25/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LVTX vs. IMRX, MOLN, THTX, TNYA, LIMN, IKT, LXEO, CGEN, LYEL, and NKTXShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Immuneering (IMRX), Molecular Partners (MOLN), Theratechnologies (THTX), Tenaya Therapeutics (TNYA), Liminatus Pharma (LIMN), Inhibikase Therapeutics (IKT), Lexeo Therapeutics (LXEO), Compugen (CGEN), Lyell Immunopharma (LYEL), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Its Competitors Immuneering Molecular Partners Theratechnologies Tenaya Therapeutics Liminatus Pharma Inhibikase Therapeutics Lexeo Therapeutics Compugen Lyell Immunopharma Nkarta Immuneering (NASDAQ:IMRX) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Does the media favor IMRX or LVTX? In the previous week, Immuneering and Immuneering both had 1 articles in the media. LAVA Therapeutics' average media sentiment score of 1.87 beat Immuneering's score of 0.93 indicating that LAVA Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Immuneering Positive LAVA Therapeutics Very Positive Do institutionals & insiders have more ownership in IMRX or LVTX? 67.7% of Immuneering shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 9.5% of LAVA Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is IMRX or LVTX more profitable? LAVA Therapeutics' return on equity of -86.38% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets ImmuneeringN/A -119.22% -99.22% LAVA Therapeutics N/A -86.38%-34.12% Which has more volatility & risk, IMRX or LVTX? Immuneering has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Do analysts recommend IMRX or LVTX? Immuneering currently has a consensus price target of $13.25, suggesting a potential upside of 226.35%. LAVA Therapeutics has a consensus price target of $3.17, suggesting a potential upside of 121.45%. Given Immuneering's stronger consensus rating and higher probable upside, research analysts clearly believe Immuneering is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60LAVA Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings and valuation, IMRX or LVTX? LAVA Therapeutics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than LAVA Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuneering$320K456.62-$61.04M-$1.96-2.07LAVA Therapeutics$11.98M3.14-$25.11M-$1.04-1.38 SummaryLAVA Therapeutics beats Immuneering on 8 of the 14 factors compared between the two stocks. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.41M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E Ratio-1.3821.1828.1020.05Price / Sales3.14286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book1.358.378.665.87Net Income-$25.11M-$55.19M$3.25B$258.55M7 Day Performance0.70%5.88%4.22%3.73%1 Month Performance9.58%17.33%10.51%11.75%1 Year Performance-30.92%4.42%34.40%18.03% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics2.3803 of 5 stars$1.43-2.1%$3.17+121.4%-32.2%$38.41M$11.98M-1.3860Positive NewsIMRXImmuneering3.1361 of 5 stars$4.24+2.7%$13.25+212.5%+230.1%$148.62M$320K-2.1660Gap UpMOLNMolecular Partners2.5584 of 5 stars$3.79+5.4%$12.00+216.3%-31.5%$145.15M$5.65M-1.98180News CoverageTHTXTheratechnologiesN/A$3.14flatN/A+119.4%$144.38M$85.87M-16.53140Positive NewsTNYATenaya Therapeutics3.9387 of 5 stars$0.86-2.3%$6.25+629.6%-79.1%$142.68MN/A-0.74110Positive NewsLIMNLiminatus PharmaN/A$5.58+3.0%N/AN/A$141MN/A0.00N/ANews CoverageGap DownIKTInhibikase Therapeutics1.4861 of 5 stars$1.88+2.2%$6.50+245.7%+10.6%$139.76MN/A-0.706News CoverageLXEOLexeo Therapeutics2.0379 of 5 stars$3.96-4.6%$16.60+319.2%-65.0%$137.77M$650K-1.2058CGENCompugen1.4458 of 5 stars$1.51-1.9%$4.00+164.9%-13.1%$137.43M$27.86M-9.4470LYELLyell Immunopharma2.5105 of 5 stars$9.49+2.7%$15.00+58.1%-61.9%$136.83M$60K-0.38270News CoverageGap UpNKTXNkarta1.768 of 5 stars$1.92+0.5%$14.33+646.5%-68.7%$135.53MN/A-1.27140Positive News Related Companies and Tools Related Companies Immuneering Alternatives Molecular Partners Alternatives Theratechnologies Alternatives Tenaya Therapeutics Alternatives Liminatus Pharma Alternatives Inhibikase Therapeutics Alternatives Lexeo Therapeutics Alternatives Compugen Alternatives Lyell Immunopharma Alternatives Nkarta Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LVTX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
